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Abstract
Aims: This study investigated the prognostic value of B type natriuretic peptide (BNP) in acute myocardial infarction (AMI) patients 
and its relation with left ventricular function and post-myocardial infarction complications.
Methods: In this cross-sectional study, plasma BNP level was measured for 42 consecutive patients (mean ± SD: 61.6 ± 10.85 years 
old) with acute ST elevation myocardial infarction (MI) and 42 healthy, age and gender matched subjects.
Result: BNP level in AMI patients were significantly higher than control group (P , 0.001). Regarding to infarct location, the highest 
BNP level measured in inferoposterior MI (BNP = 4436.63 ± 6188.159 pg/ml) and the lowest one indicated in standalone inferior MI 
(BNP = 598.83 ± 309.867 pg/ml (P = 0.071). There was significant reverse relation between BNP and EF (P = 0.006, OR = −0.47) and a 
significant relationship between BNP and killip classification (P = 0.036). There was no significant relation between diastolic and right-
ventricular function and BNP level (P = 0.61, P = 0.21). The highest BNP level was detected in LV septal rupture and false aneurysm 
(P = 0.02) and in ventricular tachycardia, but without significant relationship (P = 0.25).
Conclusion: After the onset of AMI, BNP blood level can be used as an important predictor for left ventricular dysfunction, killip clas-
sification, early mechanical complications and cardiac death.
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Introduction
Natriuretic peptides are released from the heart, in 
situations  of  pressure  and  volume  overload  of  the 
ventricles. During the last decade, B-type natriuretic 
peptide (BNP) has been proposed as a useful marker 
for the determination of acute and chronic left ven-
tricular dysfunction and the severity of systolic left 
ventricular dysfunction.1,2
BNP is a 32-amino acid neurohormone synthesized 
in the form of pre-proBNP, which is firstly cleaved to 
pro-BNP, and then to active BNP and inactive frag-
ment NT-proBNP.
In the first hours of acute myocardial infarction, BNP 
is released as a result of ischemia and necrosis of myo-
cardial cells. Afterwards, BNP rises as a result of sys-
tolic and diastolic dysfunction and increased wall stress 
of the left ventricle.3–5 There have been several evi-
dences, supporting that variation in plasma BNP level 
during acute phase of AMI, can be used as a prognostic 
factor.1 Moreover, new studies has shown that plasma 
BNP  level,  measured  in  acute  coronary  syndromes, 
independently might predict mortality rate, heart failure 
and degree of expansion of myocardial infarction.6,7
Although, BNP plasma level is measured routinely 
in AMI patients, but it is not fully determined, level of 
it how is useful in acute phase MI, for estimation of left 
ventricular ejection fraction (LVEF), diastolic dysfunc-
tion and other acute complications. This survey designed 
for elucidation of these issues. Moreover, we sought to 
investigate the prognostic value of BNP in different MI 
locations, as well as its relationship with different EF 
levels,  right  ventricular  function,  killip  classification 
(as delayed mortality rate and early AMI complications 
indicator), gender, pulmonary artery pressure and major 
electrical and mechanical complications.
Method and Materials
Study population
Study population in this cross-sectional and observa-
tional survey included forty two consecutive patients 
with  acute  ST  elevation  MI  (aged  61.6  ±  10.85, 
male = 27) who referred to emergency heart depart-
ment  of  Ghaem  Medical  Center  (Mashhad,  Iran) 
from January 2007 until January 2008. These patients 
were in the initial three days of event. Diagnosis of 
acute  myocardial  infarction  was  confirmed  via  ST 
  segment elevation in initial EKG and cardiac enzymes 
measurement.
Demographic information and vital signs, major 
risk  factors  (like  hyperlipidemia,  obesity,  diabetes 
and smoking), para-clinical data, infarction location 
and electrocardiogram results were gathered by ques-
tionnaire for each patient on admission.
During hospital stay (after the third day of admis-
sion until pre-discharge date) transthoracic echocar-
diography (TTE) was performed for all the patients 
by VIVID3 machine (GE-USA) with 2.5–3.5 MHZ 
probe according to ASE/AHA guidelines. All related 
information concerning LV size, systolic and diastolic 
function, valve dysfunction, pulmonary artery pres-
sure level, right ventricular function and mechanical 
complications of AMI were evaluated and all results 
were recorded. Afterwards, all the patients were fol-
lowed up for fourteen days after admission. Forty-
two  consecutive  healthy,  age  and  gender  matched, 
subjects were recruited for control group, as well.
The study protocol was approved by the medical 
ethics committee of the Mashhad University of Medi-
cal Sciences (MUMS).
BnP analysis
Blood samples were obtained from the patients and con-
trols, using plastic tubes containing ethylendiaminetet-
raacetic acid (EDTA) and aprotinin (50 ka/ml). Plasma 
was  separated  by  centrifuge  technique  at  300  rmp, 
4 degree Celsius and stored at minus 80 degree of Cel-
sius until analysis. Plasma BNP level was measured by 
commercial immunodimetric assay method.
Statistical analysis
SPSS for Windows, version 11.5 (SPSS Inc.,   Chicago, 
IL, USA) was used in all statistical procedures. Data 
were expressed at mean ± SD. with 95% confidence 
interval  (CI)  calculated  by  maximum  likelihood 
ratio estimation method. Differences in proportions 
were judged by χ2 test. Comparison of BNP levels 
between the two independent groups (patients with or 
  without specific cardiac diagnosis) was made using 
the   Mann-Whitney test. A two-tailed P-valve ,0.05 
was considered statistically significant.
Results
Demographic data
Demographic data of the current study, such as hyper-
tensive, hyperlipidemic and diabetic subjects, and the 
other characteristics were comparable (Table 1).BnP as indicator of left ventricular function and mechanical complications
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Plasma BnP level
Mean  plasma  BNP  level  in  the  patient  group 
(3784.57 ± 6344.97 pg/ml) was significantly higher 
than  the  control  group  (68.35  ±  69.66  pg/ml) 
(P , 0.001, Table 1).
BnP and gender, age and pulmonary 
artery pressure
Mean  plasma  BNP  level  in  male  patients  was 
3008.12 ± 6889.354 pg/ml while its level in male con-
trol subjects was 70.75 ± 76.561 pg/ml (P , 0.001). 
  Likewise, female subjects had significantly higher mean 
plasma BNP level in comparison to female controls 
(3841.75 ± 5616.783 pg/ml vs. 64.75 ± 60.048 pg/ml) 
(P , 0.05). In both groups BNP mean rates were not 
significantly different, according to gender of the par-
ticipants (P = 0.97). There was slight positive rela-
tion between BNP levels of AMI patients and age 
(P = 0.01, r = 0.39). Mean pulmonary artery pressure 
in the patient group was 41.88 ± 11.24 mmHg. Con-
sidering 35 mmHg as a cut-off point, pulmonary artery 
pressure was normal in 17 (37.5%) but increased in 25 
(62.5%) of the patients. However, there was no signif-
icant relationship between BNP level and pulmonary 
artery pressure (P = 0.36, r = 0.24) (Table 1).
BnP and MI location
The site of infarction was anterior in 41.9% (mean BNP 
level = 4208.92 ± 508.067 pg/ml), inferior-  posterior 
in 25.8% (4436.63 ± 688 pg/ml), isolated inferior wall 
infarction in 19.4% (598.83 ± 309.867 pg/ml), infe-
rior right ventricle in 12.9% (1462 ± 141.297 pg/ml) 
of  the  patients.  The  highest  level  of  BNP  was  in 
posterior-inferior MI and the lowest one in isolated 
inferior wall MI. There was no significant relation-
ship  between  BNP  levels  and  infarction  location 
(P = 0.13) (Fig. 1).
BnP and mechanical complications
Between 42 studied patients, 11 individuals (27.5%) 
had mechanical complications, between this group, two 
individuals (18%) had free wall rupture (mean BNP 
level = 7310.50 ± 6760/648 pg/ml) septal rupture in 
one patient (12091 pg/ml). Left ventricular aneurysm 
in four patients (34%) (10995.50 ± 14960.840 pg/ml), 
false aneurysm of left ventricle in one patient (9%) 
(12091 pg/ml) and left ventricular clot observed in 
three  patients  (29%)  (3969.26  ±  6486.318  pg/ml). 
Mean BNP levels was the highest in the patients with 
septal rupture and false aneurysm complications with 
significant different (P = 0.02).
ejection fraction (eF), diastolic function 
association with BnP
The average of left ventricular EF in the patients was 
47.55% ± 11.07%, and there was significant reverse 
Table 1. Demographic and base line clinical variables and 
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Figure 1. relationship BnP level (pg/ml) and MI location.Fazlinezhad et al
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association between BNP level and EF (P = 0.006, 
r = −0.47, Figure 2). EF was also strongly associated 
with age and pulmonary artery pressure (PAP) rate 
(P , 0.05).
It is understood that one of the most important 
consequences  of  acute  ischemic  attack  and  AMI 
is  diastolic  function  disorder  (DFD).  In  our  study 
28 patients had impaired left ventricular relaxation, 
(Grade one), seven in Grade two and seven others in 
advanced DDF (Grade three). There was no signifi-
cant relation between diastolic dysfunction grade and 
BNP level (P = 0.61).
BnP and right ventricular function
In  studied  group,  33  patients  (82.5%)  had  normal 
right  ventricular  function  with  mean  BNP  level 
4762.21 ± 7952.59 pg/ml, and nine patients (17.5%) 
had  right  ventricular  dysfunction  with  mean  BNP 
level 2315.43 ± 2010.25 pg/ml. There were no signif-
icant relationship between BNP mean level and right 
ventricular function (P = 0.21).
BnP and major electrical complications
Our  findings  represent  the  highest  BNP  levels 
belonging to patients with PVC, junctional rhythms 
(5515 ± 6936.3 pg/ml) (P = 0.44) and VT rhythm 
(5350.33 ± 5863.44 pg/ml) (P = 0.25). Lowest BNP 
level was measured in SA-arrest (1209.51 ± 1086.81) 
(P = 0.21), but no significant difference between BNP 
levels and other major electrical complications was 
observed (P , 0.05). (P = 0.21, Table 2).
BNP and killip classification
According  to  killip  class  1,  2,  3  and  4,  from  all 
the  patients,  13  (32.5%),  19  (47.5%),  8  (20%) 
and 2 (12.5%) patients were allocated, respectively. 
There were significant relations between BNP mean 
level and different killip classes (P = 0.036).
Discussion
AMI is a major mortality cause and in spite of recent 
diagnostic  and  therapeutic  improvements;  mortal-
ity  and  morbidity  rate  of  this  condition  is  already 
remained high. Recently, B-type natriuretic peptide 
(BNP) has been recognized as a useful marker for pre-
dicting acute and chronic left ventricular   dysfunction. 
Patients with acute ST elevation myocardial infarc-
tion (STEMI) who had higher levels of BNP have 
been shown to have worse prognosis.8–12
This study aimed to determine BNP level in AMI 
patients and its comparison to the healthy subjects. 
Besides, to evaluate the association of BNP level with 
left ventricular dysfunction and mechanical compli-
cations induced by AMI assessed, as well.
Morita et al have indicated that plasma BNP level 
was increased in 50 AMI patients in comparison to 
control group.13 In the mentioned survey, maximum 
BNP level was reported, to be prone to rise, in the first 
16 hours following admission, more than 50% of nor-
mal range, as a second peak.13 Yang et al (2007) studied 
on 246 AMI patients with 14 months follow-up and 
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Figure 2. BnP level (pg/ml) association with ejection fraction in AMI 
patients.
Table  2.  BnP  level  relationship  (in  pg/ml)  and  major 
  electrical complications (data expressed mean ± SD).
electrical  
complications
Bnp (Mean ± sD) P value  
(95% cI)
nSr (normal  
sinus rhythm)
4940.11 ± 8660.04 0.78
PAC (premature  
atrial contraction)
4719 ± 3348.82 0.25
PVC (premature  
ventricular contraction)
5515 ± 6936.3 0.44
VT (ventricular 
tachycardia)
5350.33 ± 5863.44 0.025
VF (ventricular  
fibrillation)
1358.33 ± 787.95 0.71
AVB1 (first degree  
atrioventricular block)
3405.67 ± 2475.66 0.53
AVB3 (complete  
atrioventricular block)
1761.5 ± 1086.82 0.87
SA arrest  
(sinuartrial arrest)
12091 ± 1087.82 0.21BnP as indicator of left ventricular function and mechanical complications
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investigated several indexes, as like as BNP to deter-
mine the most valuable prognostic factors for AMI 
induced mortality, They found, with multiple regres-
sion analysis, that BNP is an independent risk factor 
and an appropriate prognostic index for mortality rate 
estimation, in short and long term after AMI.14
As presented in the current study, Yoshida et al 
reported that female MI patients had significant higher 
BNP levels, than male MI patients, independent from 
their age.15 However, in our study there was no sig-
nificant difference between the genders in mean of 
BNP level, which may be due to the smaller number 
of patients as a limitation.
It seems BNP basal level would be a prognos-
tic LVEF indicator.16 Kallistratos et al understood 
that plasma BNP level is related to LVEF, and aer-
obic capacity can predict lower cardiopulmonary 
function and exercise capacity in the patients with 
impaired LVEF.17 Likewise, in our study; signifi-
cant reverse correlation between EF and BNP level 
confirmed.
In recent studies on AMI patients with ST segment 
elevation,  BNP  has  been  recognized  an  important 
prognostic  indicator  of  early  and  delayed  com-
plications of infarction,18–24 as well as Killip class. 
Grabowski et al in evaluation of 126 AMI patients 
with ST segment elevation, found that in higher Kil-
lip classes, BNP levels is more likely to be increased. 
They found out, mortality rate in Killip class I and 
BNP  below  321  mg/ml  was  1.1%  while  for  Kil-
lip more than one and BNP more than 331 mg/ml, 
this risk increases to 55.6%.25 As well in our study, 
according to higher killip class, BNP level increased 
significantly.
Kaya et al (2008) found that plasma BNP level 
in posterior AMI with right ventricular involvement 
is higher than isolated posterior infarction.26 The 
current study approved this finding, but BNP level 
in different infarction locations did not showed sig-
nificant relationship regarding this measurement.
On the other hand, it is understood, as well as pul-
monary artery pressure—an indirect indicator of left 
ventricular diastolic dysfunction and left ventricular 
volume overload-, BNP levels were also increased 
and this relationship confirmed in our study. Besides, 
present  study  findings  investigations  demonstrate 
positive correlation among BNP increased level and 
older age of the patients.
It  seems,  according  to  left  ventricular  pressure 
overload,  secondary  pulmonary  hypertension  and 
right ventricular dysfunction, BNP level is likely to 
increase.27 In our study, even though, increased BNP 
level was associated with right ventricular dysfunc-
tion, but it was not strongly confirmable.
Furthermore, Bettencourt et al27 reported relation-
ship between BNP level and diastolic function, but in 
the present study, no significant relationship between 
BNP  level  and  grade  of  diastolic  dysfunction  was 
found.
Satton et al demonstrated BNP level increases in 
accordance with MR severity,28 therefore; we investi-
gated this association in our study, and among eleven 
patients  with  mechanical  complications,  maximum 
BNP level (12091 pg/ml) was belonged to LV sep-
tal rupture cases and false aneurysm, and the lowest 
BNP level measured for LV clot.
Blangy et al reported that together with serving as 
a marker of left ventricular dysfunction, BNP level is 
marker of Ventricular Tachycardia (VT) as well, and 
increased serum BNP was associated with a higher 
incidence of VT.29 Although, there are few evidences 
about BNP levels and major electrical complications.
In our studied group, 26 patients (65%) had major 
electrical  complications  (Table  2).  Maximum  BNP 
level  was  observed  in  the  patients  with  premature 
ventricular contraction (PVC) and ventricular tachy-
cardia (VT) disorder, while the lowest BNP level was 
measured in the patients with sinuartrial arrest rhythm 
disorder. However, generally there was no significant 
difference  between  subgroups  of  the  patients  with 
other electrical complications.
conclusion
The findings of this study confirmed previous hypoth-
eses and brought important information, regarding the 
BNP prognostic role on acute MI and acute complica-
tions happening after 3rd days of admission, mean-
while pre-discharge time.
Accordingly, we assumed, the first, plasma BNP 
level could be useful as an important and valid pre-
dictor of left ventricular systolic dysfunction, as a 
reverse relation of BNP levels and LVEF is observed 
in AMI patients. Second, BNP elevations in higher 
Killip  classifications  and  mechanical  complica-
tions, strongly confirmed prognostic role of BNP in 
AMI patients. Therefore, it seems that measurement Fazlinezhad et al
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of plasma BNP level in early phase of myocardial 
infarction may be useful as a non-invasive method for 
identification of individuals, at higher risk of compli-
cations and post-MI mortality.
Limitations
Effect of type of treatment, on BNP level was not 
assessed  in  present  study.  Besides,  we  could  not 
recruit more than forty two patients due to the high 
cost  of  plasma  BNP  measurement.  Finally,  short-
term follow up of our patients, confined to 14 days is 
another limitation.
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